Pulmonary defense mechanisms against pneumonia and sepsis

Current Opinion in Pulmonary Medicine

Volumn 14, Issue 3, 2008, Pages 260-265

  Tsai, Katherine S ^a   Grayson, Mitchell H ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Defense; Dendritic cell; Lung; Pneumonia; Sepsis

Indexed keywords

BUTYRIC ACID; CD14 ANTIGEN; CD40 LIGAND MONOCLONAL ANTIBODY; HEME OXYGENASE 1; HIGH MOBILITY GROUP B1 PROTEIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 1; TOLL LIKE RECEPTOR 2; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 5; TOLL LIKE RECEPTOR 6; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TOLL LIKE RECEPTOR 9;

ANTIGEN PRESENTING CELL; BACTERIAL CELL WALL; CHLAMYDOPHILA PNEUMONIAE; COMMUNITY ACQUIRED PNEUMONIA; DENDRITIC CELL; GRAM POSITIVE BACTERIUM; HOST RESISTANCE; IMMUNE RESPONSE; INFECTION PREVENTION; INFECTION RESISTANCE; INNATE IMMUNITY; LEGIONELLA PNEUMOPHILA; MYCOPLASMA PNEUMONIA; MYCOPLASMA PNEUMONIAE; NONHUMAN; PNEUMONIA; REVIEW; SEPSIS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PNEUMONIA; STREPTOCOCCUS PNEUMONIAE; THERAPY EFFECT; TISSUE INJURY; TREATMENT OUTCOME; TREATMENT RESPONSE; VIRUS PNEUMONIA;

HUMANS; IMMUNITY, CELLULAR; IMMUNITY, NATURAL; LUNG; PNEUMONIA; SEPSIS;

EID: 42449106990     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e3282f76457     Document Type: Review

References (55)

1. Agnus DC, Linde-Zwirble WT, Lidicker J, et al. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001; 29:1303-1310.
2. Martin GS, Mannino DM, Eaton S, Moss M. The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 2003; 348:1546-1554.
3. Bartlett JG, Mundy LM. Community-acquired pneumonia. N Engl J Med 1995; 333:1618-1624.
4. Zhang P, Summer WR, Bagby GJ, Nelson S. Innate immunity and pulmonary host defense. Immunol Rev 2000; 173:39-51.
5. Klotman ME, Chang TL. Defensins in innate antiviral immunity. Nat Rev Immunol 2006; 6:447-456.
6. Lehrer RI, Ganz T. Defensins of vertebrate animals. Curr Opin Immunol 2003; 15:396-401.
7. Sim RB, Clark H, Hajela, Mayilan R. Collectins and host defence. In: Chadwick DJ, Goode J (editors). Innate immunity to pulmonary infection. Novartis Foundation Symposium; 279. Chichester: Wiley; 2006. pp.170-186. This book transcribes an international meeting of lung defense experts held at the University of Cape Town Medical School in South Africa from November 28-30, 2005, discussing innate immune defenses in the lung.
8. Van de Wetering JK, Van Golde LMG, Batenburg JJ. Collectins: players of the innate immune system. Eur J Biochem 2004; 271:229-249.
9. Garlanda C, Bottazi B, Bastone A, Mantovani A. Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu Rev Immunol 2004; 23:337-366.
10. Ekdahl K, Truedsson L, Sjoholm AG, et al. Complement analysis in adult patients with a history of bacteremic pneumococcal infections or recurrent pneumonia. Scand J Infect Dis 1995; 27:111-117.
11. Walport MJ. Complement. N Engl J Med 2001; 344:1058-1066; 1141-1144.
12. Carroll MC. The complement system in regulation of adaptive immunity. Nat Immunol 2004; 5:981-986.
13. Petersen SV, Thiel S, Jensenius JC. The mannan-binding lectin pathway of complement activation: biology and disease association. Mol Immunol 2001; 38:133-149.
14. Roozendaal R, Carroll MC. Emerging patterns in complement-mediated pathogen recognition. Cell 2006; 125:29-32.
15. MacMicking J, Xie QW, Nathan CF. Nitric oxide and macrophage function. Annu Rev Immunol 1997; 15:323-350.
16. Segal AW. How neutrophils kill microbes. Annu Rev Immunol 2005; 23:197-223.
17. Underhill DM, Ozinksy A. Phagocytosis of microbes: complexity in action. Annu Rev Immunol 2002; 20:825-852.
18. Bryceson YT, March ME, Ljunggren HG, Long EO. Activation, coactivation, and costimulation of resting human natural killer cells. Immunol Rev 2006; 214:73-91.
19. Akira S, Kaisho T, Takeda K. Toll-like receptors. Annu Rev Immunol 2003; 21:335-376.
20. Sugawara I, Yamada H, Li C, et al. Mycobacterial infection in TLR2 and TLR6 knockout mice. Microbiol Immunol 2003; 47:327-336.
21. Takeuchi O, Kawai T, Sanjo H, et al. TLR6: a novel member of an expanding toll-like receptor family. Gene 1999; 231:59-65.
22. Myhre AE, Aasen AO, Thiemermann C, Wang JE. Peptidoglycan: an endotoxin in its own right? Shock 2006; 25:227-235.
23. Trent MS, Stead CM, Tran AX, Hankins JV. Diversity of endotoxin and its impact on pathogenesis. J Endotoxin Res 2006; 12:205-223.
24. Dixon DR, Darveau RP. Lipopolysaccharide heterogeneity: innate host responses to bacterial modification of lipid a structure. J Dent Res 2005; 84:584-595.
25. Hoshino K, Takeuchi O, Kawai T, et al. Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J Immunol 1999; 162:3749-3752.
26. Hayashi F, Smith KD, Ozinsky A, et al. The innate immune response to bacterial flagellin is mediated by Toll-like receptor 5. Nature 2001; 310:1099-1103.
27. Triantafilou K, Vakakis E, Orthopoulos G, et al. TLR8 and TLR7 are involved in the host's immune response to human parechovirus 1. Eur J Immunol 2005; 35:2416-2423.
28. Bauer S, Kirschning CJ, Hacker H, et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc Natl Acad Sci USA 2001; 98:9237-9242.
29. Hemmi H, Takeuchi O, Kawai T, et al. A Toll-like receptor recognizes bacterial DNA. Nature 2000; 408:740-745.
30. Zhang D, Zhang G, Hayden MS, et al. A Toll-like receptor that prevents infection by uropathogenic bacteria. Science 2004; 303:1522-1526.
31. Kowalski MP, Dubouix-Bourandy A, Bajmoczi M, et al. Host resistance to lung infection mediated by major vault protein in epithelial cells. Science 2007; 317:130-132. This paper demonstrates the importance of major vault protein in lung defense against infection.
32. Grayson MH. Lung dendritic cells and the inflammatory response. Ann Allergy Asthma Immunol 2006; 96:643-651. A comprehensive review of the role of conventional and plasmacytoid dendritic cells in inducing and modulating immune responses in the lung.
33. Zammit DJ, Cauley LS, Pham Q-M, Lefrancois L. Dendritic cells maximize the memory CD8 T cell response to infection. Immunity 2005; 22:561-570.
34. Grayson MH, Cheung D, Rohlfing MM, et al. Induction of high-affinity IgE receptor on lung dendritic cells during viral infection leads to mucous cell metaplasia. J Exp Med 2007; 204:2759-2769.
35. Legge KL, Braciale TJ. Accelerated migration of respiratory dendritic cells to the regional lymph nodes is limited to the early phase of pulmonary infection. Immunity 2003; 18:265-277.
36. Hotchkiss RS, Tinsley KW, Swanson PE, et al. Depletion of dendritic cells, but not macrophages, in patients with sepsis. J Immunol 2002; 168:2493-2500.
37. Tinsely KW, Grayson MH, Swanson PE, et al. Sepsis induces apoptosis and profound depletion of splenic interdigitating and follicular dendritic cells. J Immunol 2003; 171:909-914.
38. Hotchkiss RS, Tinsely KW, Swanson PE, et al. Sepsis-induced apoptosis causes progressive profound depletion of B and CD4+ T lymphocytes in humans. J Immunol 2001; 166:6952-6963.
39. Hotchkiss RS, Swanson PE, Freeman BD, et al. Apoptotic cell death in patients with sepsis, shock, and multiple organ dysfunction. Crit Care Med 1999; 27:1230-1251.
40. Felmet KA, Hall MW, Clark RS, et al. Prolonged lymphopenia, lymphoid depletion, and hypoprolactinemia in children with nosocomial sepsis and multiple organ failure. J Immunol 2005; 174:3765-3772.
41. Toti P, De Felice C, Occhini R, et al. Spleen depletion in neonatal sepsis and chorioamnionitis. Am J Clin Pathol 2004; 122:765-771.
42. Hotchkiss RS, Osmon SB, Chang KC, et al. Accelerated lymphocyte death in sepsis occurs by both the death receptor and mitochondrial pathways. J Immunol 2005; 174:5110-5118.
43. Le Tulzo Y, Pangault C, Gacouin A, et al. Early circulating lymphocyte apoptosis in human septic shock is associated with poor outcome. Shock 2002; 18:487-494.
44. Guisset O, Dilhuydy MS, Thiebaut R, et al. Decrease in circulating dendritic cells predicts fatal outcome in septic shock. Intensive Care Med 2007; 33:148-152. This study demonstrates the potential use of dendritic cell count as a biomarker predicting disease severity in septic shock patients.
45. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992; 101:1644-1655.
46. Schwulst SJ, Grayson MH, DiPasco PJ, et al. Agonistic monoclonal antibody against CD40 receptor decreases lymphocyte apoptosis and improves survival in sepsis. J Immunol 2006; 177:557-565.
47. Oberholzer C, Oberholzer A, Bahjat FR, et al. Targeted adenovirus induced expression of IL-10 decreases thymic apoptosis and improves survival in murine sepsis. Proc Natl Acad Sci USA 2001; 98:11503-11508.
48. Iwata A, Stevenson VM, Minard A, et al. Over-expression of Bcl-2 provides protection in septic mice by a trans effect. J Immunol 2003; 171:3136-3141.
49. Hotchkiss RS, Swanson PE, Knudson CM, et al. Overexpression of Bcl-2 in transgenic mice decreases apoptosis and improves survival in sepsis. J Immunol 1999; 162:4148-4156.
50. Hotchkiss RS, Chang KC, Swanson PE, et al. Caspase inhibitors improve survival in sepsis: a critical role of the lymphocyte. Nat Immunol 2000; 1:496-501.
51. Braun JS, Novak R, Herzog KH, et al. Neuroprotection by a caspase inhibitor in acute bacterial meningitis. Nat Med 1999; 5:298-302.
52. Sarady-Andrew JK, Liu F, Gallo D, et al. Biliverdin administration protects against endotoxin-induced acute lung injury in rats. Am J Physiol Lung Cell Mol Physiol 2005; 289:L1131-L1137.
53. Wang H, Bloom O, Zhang M, et al. HMGB1 as a late mediator of endotoxin lethality in mice. Science 1999; 285:248-251.
54. Yang H, Ochani M, Li J, et al. Reversing established sepsis with antagonists of endogenous high-mobility group box 1. Proc Natl Acad Sci USA 2004; 101:296-301.
55. Zhang L-T, Yao Y-M, Lu J-Q, et al. Sodium butyrate prevents lethality of severe sepsis in rats. Shock 2007; 27:672-677. This study provides evidence that sodium butyrate may be an effective treatment for severe sepsis.